Jai Parekh
Interventional Cardiology · Omaha, NENPI 1578915781
Payments from drug & device makers
What this record shows
This record is dominated by grants: $34,500 of the $44,258 with a category attached, or 78.0%. 21 manufacturers reported payments, led by Medtronic at 51.9% of the total. Reporting peaked in 2023 at $36,182 and has fallen 88.4% since, to $4,199 in 2025.
Across 137 payments — averaging $323.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$23K
- Abbott$18K
- Edwards Lifesciences$2K
- Boston Scientific$447
- AbbVie$303
- Cardiovascular Systems Inc.$120
- plus $498 from 15 others
What the payments were for
- Grants$34,50078%
- Travel & lodging$4,20510%
- Food & beverage$5,33212%
- Education$2210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 30 | $22,968 |
| Abbott | 48 | $17,909 |
| Edwards Lifesciences | 25 | $2,013 |
| Boston Scientific | 9 | $447 |
| AbbVie(2 entities) | 4 | $303 |
| Cardiovascular Systems Inc. | 1 | $120 |
| Abiomed | 2 | $94 |
| Inari Medical, Inc. | 4 | $84 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $79 |
| Bridgebio Pharma, Inc. | 1 | $39 |
| Harrow Eye, LLC | 1 | $26 |
| Novartis | 1 | $23 |
| Lantheus Medical Imaging, Inc. | 1 | $22 |
| Shockwave Medical, Inc | 1 | $22 |
| Biosense Webster, Inc. | 1 | $19 |
| AstraZeneca | 1 | $16 |
| Getinge USA Sales, LLC | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Biotronik Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Livanova USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$22,109
- TRICLIP$1,440
- MitraClip$1,167
- PASCAL$1,047
- SAPIEN 3 Ultra RESILIA$397
- SYMPLICITY G3$299
- HeartMate 3 Left Ventricular Dev$206
- CardioMEMS HF System$202
- XEN GLAUCOMA TREATMENT SYSTEM$143
- Optis Coronary Imaging System$137
- EVOQUE$124
- Diamondback Coronary$120
- WATCHMAN FLX$118
- CROSSBOSS$105
How this compares
$44,258 in reported general payments places this provider in the 85th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 30 | $22,571 |
| EliquisApixaban | 24 | $17,713 |
| EntrestoSacubitril/Valsartan | 14 | $15,137 |
| FarxigaDapagliflozin Propanediol | 12 | $11,362 |
| Metoprolol Succinate | 48 | $692 |
| Ezetimibe | 11 | $450 |
| ClopidogrelClopidogrel Bisulfate | 49 | $441 |
| Metoprolol Tartrate | 47 | $364 |
| Potassium Chloride | 12 | $316 |
| Atorvastatin Calcium | 19 | $271 |
| Amlodipine Besylate | 20 | $169 |
| Spironolactone | 25 | $145 |
| Furosemide | 28 | $143 |
| Rosuvastatin Calcium | 26 | $121 |
| Warfarin Sodium | 24 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $15 | $22,57130 claims |
| NovartisEntresto | $23 | $15,13714 claims |
| AstraZenecaFarxiga | $16 | $11,36212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Omaha
- Himanshu AgarwalOmaha$541K
- Poonam VelagapudiOmaha$142K
- Andrew GoldsweigOmaha$49K
- Scott CarolloOmaha$19K
- Shahbaz MalikOmaha$17K
- Toufik HaddadOmaha$14K
- Charles OlsonOmaha$12K
- Haysam AkkadOmaha$11K
- Ajaypaul SukhiOmaha$9K
- Filip OleszakOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.